Editor Insights

Will payers push for services to be provided on an outpatient basis, thus placing financial burden upon the patient, or will they allow the oncologist or facility to use their discretion as to where the infusion will take place?

Clinical pathways may require a deeper consideration of the patient experience in order to achieve the goals of the Triple Aim, according to Winston Wong, PharmD.

While CAR T-cell therapies fill an unmet need in hematologic malignancies, they are not without risk and cost burdens, according to Winston Wong, PharmD.